Equibles does not estimate personal net worth.
Get an email with a short summary when Mirum Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get MIRM alertsChris Peetz is recorded as CEO at Mirum Pharmaceuticals, Inc. (MIRM). Chris Peetz has spoken on 19 earnings calls and 3 other investor events across 1 company, most recently for Mirum Pharmaceuticals, Inc. on November 3, 2026. Mirum Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Mirum Pharmaceuticals, Inc. includes Christopher Peetz (CEO), Michael Grey (CEO), Eric Bjerkholt (CFO) and 6 others.
“Third quarter was another strong period for Mira, both commercially and across our clinical programs. We generated $186 million in third quarter net product sales.”
“Livmarly is approved in two different indications, cholestatic pyritis due to Allergyle syndrome and cholestatic pyritis due to PFIC. And first approval in Allergyle syndrome continues to be a growth driver, so we, across the board, continue to see new patient starts.”
“So happy to dive into it and break some of that down. First comment, I will be making forward-looking statements. So refer folks to our SEC filings for full disclosure of risk factors.”
“First, point out that we make some forward-looking statements. So refer people to the SEC filings for more complete risk factor disclosure. And a couple of intro words on the cadence of events over the year for Miriam.”
“At Merrim, we're growing a rare disease leader focused on delivering high-impact medicines for often overlooked diseases. This quarter demonstrates continued progress with strong commercial execution on our approved medicines as we head into the potential launch of our fourth commercial medicine later this year.”
Biotechnology · Healthcare
CEO
